occurrence. Therefore, there are urgent needs for investigating the underlying mechanisms of CC progression and chemotherapy resistance to develop new potent therapies for CC treatment.
Forkhead box O3 (FOXO3), also known as FOXO3a, is one of FOXO subfamily members (Bullock et al., 2013) . Emerging evidence indicates that FOXO3, characterized by a "Forkhead box" DNA-binding domain, plays important roles in carcinogenesis and chemotherapeutic resistance (Gomes, Zhao, & Lam, 2013) . For example, Yang et al. (2010) showed that inhibited FOXO3 expression and activation enhanced the resistance to AZD6244 treatment in cells of various tumors. Wei et al. (2016) demonstrated that impaired FOXO3 expression contributed to the chemoresistance of ovarian cancer cells.
Due to the previous findings, we wonder whether FOXO3 is involved in CC progress and drug resistance or not. Hence, we investigated the biological effects of FOXO3 on the proliferation and drug resistance of human CC cells and explored the possible mechanisms.
| METHODS AND MATERIALS

| Cell lines
HCT116 and DLD1 human cells were bought from ATCC. These cells were cultured in McCoy's 5A media (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) at 37°C in 5% CO 2 . Doxorubicin-resistant HCT116 DR cells were established as previously described (Choi, Kim, Choi, Kim, & Lee, 1996) .
| Plasmid construction and transfection
Scramble shRNA and FOXO3 shRNA were synthesized and cloned into LV3 vector (Sangon, Shanghai). FOXO3 and MDR1 were amplified and subcloned into MSCV-PIG vector to construct FOXO3 overexpression plasmid and MDR1 overexpression plasmid, respectively. Cell transfection was conducted through Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
| Western blot analysis
Primary antibodies for FOXO3 and MDR1 were obtained from Cell Signaling. Cells were harvested and lysed in RIPA (Beytime, Shanghai, China). Equal amount of proteins from each group was subjected to 10% SDS-PAGE and transferred to nitrocellulose membrane. Prepared blots were blocked by TBS containing 3% BSA. Subsequently, the membrane was incubated with the specific primary antibodies (1:500 or 1:1,000 dilution) followed by HRP-linked secondary antibodies.
| Dual luciferase reporter assay
Wild-type MDR1 promoter harboring potential FOXO3 binding sites was amplified and subcloned into pGL3 basic vector (Promega, Madison, WI, USA) to construct pGL3-MDR1-WT-promoter plasmid. The mutant MDR1 promoter harboring the mutant FOXO3 binding sequences was amplified to construct pGL3-MDR1-mutpromoter plasmid. HCT116 cells were co-transfected with different reporter vectors (pGL3 basic vector, pGL3-MDR1-WT-promoter, or pGL3-MDR1-mut-promoter) as well as FOXO3 overexpression plasmid or the empty vector. At 48 hr, luciferase activity was measured via the dual luciferase assay system (Promega).
| MTT assay
Colon cancer cells (10 3 cells/well) were inoculated into 96-well plates, and 0.5 mg/ml MTT solution was added into each well for 4 hr. Then, the solution was discarded and replaced with 150 µl of DMSO to lyse the crystalline precipitate. Absorbance at 545 nm was detected using a microplate reader.
| Quantitative PCR (qPCR) analysis
Quantitative PCR was conducted with 0.5 μg total RNA using the ABI 7500 System (Life Technologies, NY, USA). Primer sequences were listed below: FOXO3 fwd, 5′-CGGACAAACGGCTCACTCT-3′; FOXO3 rev, 5′-GGACCCGCATGAATCGACTAT-3′; MDR1 fwd, 5′-TTGGCTGATGTTTGTGGGAAG-3′; MDR1 rev, 5′-CCAAAAATGAGTAGCACGCCT-3′.
| Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation experiment was performed according to the previous paper (Wu et al., 2015) to examine the binding between FOXO3 and MDR1 promoter. In brief, cells were fixed, lysed and sonicated. After centrifugation, soluble chromatin fragments were pretreated with protein G-agarose and subsequently incubated with either FOXO3 antibody (Cell Signaling) or rabbit IgG (Cell Signaling) overnight at 4°C. Extracted DNA was analyzed by PCR. The primers for ChIP assay were as follows: MDR1 promoter: Forward: 5′-TACACCTCTTTAGGGTTAAGGCA-3′ Reverse: 5′-GGACGTGAAGATAGACAACTGGT-3′.
| Statistical analysis
Data were generated from at least three separate tests. SPSS 10.0 software was employed for statistical analysis. In cases of statistical significance, the ranked parameters were compared by one-way ANOVA analysis or Student's t test. p < 0.05 indicated significance. 
| MDR1 is a direct downstream target of FOXO3
Forkhead box O3 overexpression stimulated MDR1 mRNA (Figure 3a , p < 0.001) and protein expression (Figure 3b ) in HCT116 cells, compared to the control group. In contrast, HCT116 cells transfected with FOXO3 shRNA plasmid had lower MDR1 mRNA (Figure 3c , p < 0.05) and protein levels ( Figure 3d ) compared with cells transfected with empty vector. Potential targets of FOXO3 were predicted by rVista analysis, and Figure 3e demonstrated that there was a potential FOXO3 binding site in MDR1 promoter. Figure  3f revealed that FOXO3 overexpression plasmid enhanced the luciferase activity of the reporter plasmid containing wide-type MDR1 promoter compared with the empty vector (p < 0.001), whereas it had no significant effect on the luciferase activity of the reporter plasmid containing mutant MDR1 promoter. In addition, FOXO3 shRNA inhibited the luciferase activity of the reporter plasmid containing widetype MDR1 promoter compared with control (p < 0.001), whereas FOXO3 shRNA had no significant effect on the luciferase activity of the reporter plasmid containing mutant MDR1 promoter (Figure 3g ). Besides, CHIP assay further proved that FOXO3 directly bind to the seed region in MDR1 promoter (Figure 3h ).
| MDR1 had tumor-promoting effects on the proliferation and drug resistance of CC cells
Quantitative PCR results showed that HCT116 DR cells had higher MDR1 mRNA level than HCT116 cells (Figure 4a , p < 0.001). On the other hand, 4 μM doxorubicin time-dependently upregulated MDR1 expression in HCT116 cells (Figure 4b , p < 0.05 and p < 0.001 for 24 and 48 hr, respectively). Thus, we speculated that there was a positive relationship between MDR1 expression and the proliferation and drug resistance of CC cells. To test the above hypothesis, HCT116 cells were transfected with MDR1 overexpression plasmid or empty vector. Figure 4c,d showed that 
| DISCUSSION
The current treatments for CC include surgery, radiation therapy, chemotherapy, and targeted therapy (Li, Shen, Zhou, & Yu, 2018) . People with early-stage CC may be cured via surgery, whereas CC patients at the advanced stages treated with the combined chemotherapy are usually not curable due to drug resistance (Ma et al., 2012; Yu et al., 2017) . Increasing evidence suggests that FOXO3 played important roles in CC development and metastasis (Bullock et al., 2013; Tenbaum et al., 2012) . Hence, we want to explore the possible relationship between FOXO3 and the proliferation and drug resistance of CC cells to obtain better clinical therapy for advanced CC patients. To our delight, the results of MTT and cell count assay indicated that FOXO3 overexpression fostered the proliferation of HCT116 and DLD1 cells in a time-dependent fashion.
At present, the application of doxorubicin, a DNA-intercalating anthracycline antibiotic, in combination with other anti-tumor drugs exhibits good therapeutic effects against late-stage CC (Qu et al., 2015) . However, chemoresistance is a frequent event and inhibits the clinical application of chemotherapy drugs. Hence, a better understanding about the molecular mechanisms underlying the CC cell resistance to chemotherapy drugs will be very crucial for chemotherapy. In this study, HCT116 DR cells had higher mRNA level of FOXO3 compared to their parental cells. Moreover, doxorubicin time-dependently stimulated FOXO3 expression in HCT116 cells, which suggested that the upregulation of FOXO3 was a consistent step during the conversion process from initial doxorubicin sensitivity to doxorubicin resistance in CC cells. In addition, FOXO3 overexpression enhanced the resistance of HCT116 cells to doxorubicin, whereas FOXO3 downregulation inhibited the doxorubicin resistance of HCT116 DR cells. Taken together, FOXO3 may positively mediate the doxorubicin resistance of HCT116 cells.
It is generally accepted that activated FOXO3, one of the FOXO transcription factors, accumulates in the nucleus and then bind to DNA or other transcriptional factors to modulate the expressions of its specific target genes related to cell proliferation, apoptosis, and other critical cellular processes (Burgering & Kops, 2002; Myatt & Lam, 2007) . To identify the novel targets of FOXO3 in CC cells, rVista analysis and dual luciferase reporter assay were carried out. The results showed that FOXO3 overexpression enhanced the luciferase activity of pGL3-MDR1-WT-promoter plasmid, whereas it had little effect on the luciferase activity of pGL3-MDR1-mut-promoter plasmid, which suggested that FOXO3 may be able to bind to the seed region in MDR1 promoter and stimulated MDR1 expression. Moreover, FOXO3 overexpression significantly stimulated MDR1 expression, whereas FOXO3 shRNA had the opposite effect. In addition, CHIP assay further demonstrated that there was direct binding between FOXO3 protein and MDR1 promoter in HCT116 cells. Hence, these above results suggested that FOXO3 was a binding partner of MDR1 promoter and positively regulated MDR1 expression in HCT116 cells.
MDR1, also known as P-gp, ABCB1, or CD243, belongs to ATP-binding cassette family and pumps various foreign substances across the cell membrane. Recent studies found that the MDR1 had important functions in the drug resistant of various tumors. For example, Pan, Miao, and Chen (2018) demonstrated that germacrone inhibited MDR1 expression and subsequently decreased the adriamycin resistance of chronic myelogenous leukemia cells. Zhu, Lv, Yan, and Gao (2013) showed that the knockdown of MDR1 enhanced the adriamycin sensitivity of drug-resistant gastric cancer cell line SGC7901-MDR1. Besse et al. (2018) found that MDR1 overexpression was the most important change in carfilzomib-resistant multiple myeloma cells. Moreover, many studies proved that there was positive relationship between MDR1 and the resistance to various drugs in CC treatment, such as doxorubicin (Du et al., 2018; Yan, Zhao, & Zhang, 2017) , oxaliplatin (Zhou et al., 2017) , and irinotecan (Paule et al., 2010) . In this study, qPCR data further demonstrated that FOXO3 overexpression had little effects on the expression of other five members of ATP-binding cassette family in HCT116 cells, including ABCB2, ABCA1, ABCA2, ABCG1, and ABCG2 ( Figure S1 ). Moreover, we found that MDR1 overexpression completely restored FOXO3 knockout induced the decrease in the proliferation and doxorubicin resistance of HCT116 cells. Hence, our data suggested that MDR1 was a functional downstream effector of FOXO3 in CC cells.
It is well-known that the roles of FOXO3 in cancer progress are complicated. Previous studies demonstrated that FOXO3 exhibited suppressive effects on various tumors. For instance, Park et al. (2016) found that FOXO3 activation restricted triple-negative breast cancer (TNBC) cell survival and proliferation. Wang et al. (2015) showed that FOXO3 contributed to rhein-stimulated Bim expression and apoptosis in both MCF7 breast cancer cells and HepG2 hepatoma cells. In contrast, more and more studies described the tumor-promoting actions of FOXO3. For example, Zhang et al. (2016) found that activated FOXO3 negatively modulated the expression of metastasis suppressor gene nm23-H1 in A549 non-small-cell lung cancer cells. Tenbaum et al. (2012) showed that FOXO3 may foster CC metastasis via co-modulation of metastasis-related genes. Based on our above findings, we here found that FOXO3 promoted the proliferation and drug resistance of CC cells by activating MDR1 expression.
In summary, our present study characterized that FOXO3 can directly bind to MDR1 promoter and enhanced MDR1 expression, which subsequently fostered the proliferation and doxorubicin resistant of human CC cells. Therefore, our finding suggested that FOXO3 may be a potential therapeutic target during CC treatment.
| CONCLUSION
Forkhead box O3 has a tumor-promoting role in CC cells via targeting MDR1.
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